Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study.
bimekizumab
biologic therapy
effectiveness
hidradenitis suppurativa
safety
Journal
The Australasian journal of dermatology
ISSN: 1440-0960
Titre abrégé: Australas J Dermatol
Pays: Australia
ID NLM: 0135232
Informations de publication
Date de publication:
19 Jun 2024
19 Jun 2024
Historique:
revised:
01
06
2024
received:
05
02
2024
accepted:
10
06
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
19
6
2024
Statut:
aheadofprint
Résumé
In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS-PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Australasian College of Dermatologists.
Références
Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045–1058.
Sayed C, Shi V, Hsiao J, Kokolakis G, Kirby B, Piguet V, et al. Bimekizumab efficacy by prior biologic treatment in patients with moderate to severe hidradenitis suppurativa: 48‐week pooled data from the randomized, double‐blind, placebo‐controlled, multicenter BE HEARD I and II phase 3 trials. SKIN J Cutan Med. 2024;8(1):s349.
Orenstein LA, Shi V, Lev‐Tov H, Prens E, Podda M, Fujita H, et al. Bimekizumab impact on pain in moderate to severe hidradenitis suppurativa: week 16 results from BE HEARD I & II. SKIN J Cutan Med. 2024;8(1):s350.
Zouboulis CCG, Forman S, Weisman J, Szepietowski JC, Prens EP, Fujita H, et al. Bimekizumab efficacy and safety in patients with moderate to severe hidradenitis suppurativa: Analysis of pooled data from BE HEARD I & II phase 3, randomised, double‐blind, placebo‐controlled, multicentrestudies. EADV Congress 2023.
Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double‐blind placebo‐controlled randomized clinical trial. JAMA Dermatol. 2021;157(11):1279–1288.
Molinelli E, Gambini D, Maurizi A, De Simoni E, Sapigni C, Belleggia S, et al. Bimekizumab in hidradenitis suppurativa: a valid and effective emerging treatment. Clin Exp Dermatol. 2023;48(11):1272–1274.
Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142–152.